deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01737502

Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer

A Phase I-II Trial of Combined PKCι and mTOR Inhibition for Patients With Advanced or Recurrent Lung Cancer (NSCLC and SCLC) Without Standard Treatment Options

Sponsor: Mayo Clinic

Conditions Extensive Stage Small Cell Lung Carcinoma Lung Adenocarcinoma Recurrent Non-Small Cell Lung Carcinoma Recurrent Small Cell Lung Carcinoma Squamous Cell Lung Carcinoma Stage IIIA Non-Small Cell Lung Cancer Stage IIIB Non-Small Cell Lung Cancer Stage IV Non-Small Cell Lung Cancer
Interventions Auranofin Laboratory Biomarker Analysis Pharmacological Study Sirolimus
Updated 19 times since 2017 Last updated: Aug 19, 2025 Started: May 14, 2014 Primary completion: Apr 24, 2023 Completion: Apr 24, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Extensive Stage Small Cell Lung Carcinoma and Lung Adenocarcinoma, this trial is completed. The trial is conducted by Mayo Clinic and has accumulated 19 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshot~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Feb 2019 · 5 months · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2020 · 13 months · monthly snapshot~Apr 2020 – ~Dec 2020 · 8 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Dec 2021 · 7 months · monthly snapshot~Dec 2021 – ~Jul 2022 · 7 months · monthly snapshot~Jul 2022 – ~Aug 2023 · 13 months · monthly snapshot~Aug 2023 – ~Apr 2024 · 8 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – present · 9 months · monthly snapshot

Change History

19 versions recorded

  1. Oct 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2025 — Oct 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  5. Apr 2024 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

▶ Show 14 earlier versions

  1. Aug 2023 — Apr 2024 [monthly]

    Completed PHASE1_PHASE2

    Status: Recruiting → Completed

  2. Jul 2022 — Aug 2023 [monthly]

    Recruiting PHASE1_PHASE2

  3. Dec 2021 — Jul 2022 [monthly]

    Recruiting PHASE1_PHASE2

  4. May 2021 — Dec 2021 [monthly]

    Recruiting PHASE1_PHASE2

  5. Jan 2021 — May 2021 [monthly]

    Recruiting PHASE1_PHASE2

  6. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  7. Apr 2020 — Dec 2020 [monthly]

    Recruiting PHASE1_PHASE2

  8. Mar 2019 — Apr 2020 [monthly]

    Recruiting PHASE1_PHASE2

  9. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE1_PHASE2

  10. Sep 2018 — Feb 2019 [monthly]

    Recruiting PHASE1_PHASE2

  11. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE1_PHASE2

  12. Sep 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  13. Feb 2017 — Sep 2017 [monthly]

    Recruiting PHASE1_PHASE2

  14. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

May 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Mayo Clinic
  • National Cancer Institute (NCI)
Data source: Mayo Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations